` BIOPOR (Bioporto A/S) vs OMX Copenhagen 25 Comparison - Alpha Spread

BIOPOR
vs
OMX Copenhagen 25

Over the past 12 months, BIOPOR has underperformed OMX Copenhagen 25, delivering a return of -18% compared to the OMX Copenhagen 25's 10% drop.

Stocks Performance
BIOPOR vs OMX Copenhagen 25

Loading

Performance Gap
BIOPOR vs OMX Copenhagen 25

Loading
BIOPOR
OMX Copenhagen 25
Difference

Performance By Year
BIOPOR vs OMX Copenhagen 25

Loading
BIOPOR
OMX Copenhagen 25
Add Stock

Competitors Performance
Bioporto A/S vs Peers

OMX Copenhagen 25
BIOPOR
ABBV
AMGN
GILD
VRTX
Add Stock

Bioporto A/S
Glance View

Market Cap
610.1m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
0.83 DKK
Overvaluation 41%
Intrinsic Value
Price
Back to Top